Novel Agents in NHL, FDA Approval in Myeloma, Combination Trials With Atezolizumab, and More

MRD Testing Requires Prospective Data to Assess Clinical Utility in Breast Cancer

Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes

Dr Sabari on Barriers to Biomarker Testing in NSCLC

Dr Backhus on Surgical Eligibility in Borderline Resectable NSCLC